191 related articles for article (PubMed ID: 31082494)
1. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.
Margalit DN; Haddad RI; Tishler RB; Chau NG; Schoenfeld JD; Bakst RL; Misiukiewicz KJ; Gupta V; Posner M; Hanna GJ; Mahmood U; Rawal B; Catalano PJ; Rath L; Bacay A; McHugh P; Rabinowits G
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):132-139. PubMed ID: 31082494
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
3. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.
Fury MG; Lee NY; Sherman E; Ho AL; Rao S; Heguy A; Shen R; Korte S; Lisa D; Ganly I; Patel S; Wong RJ; Shaha A; Shah J; Haque S; Katabi N; Pfister DG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):479-86. PubMed ID: 24074921
[TBL] [Abstract][Full Text] [Related]
6. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients.
Willey CD; Murphy BA; Netterville JL; Burkey BB; Shyr Y; Shakhtour B; Kish B; Raben D; Chen C; Song JI; Kane MA; Cmelak AJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1323-31. PubMed ID: 17289289
[TBL] [Abstract][Full Text] [Related]
7. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
Kovács AF; Mose S; Böttcher HD; Bitter K
Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
[TBL] [Abstract][Full Text] [Related]
8. Role of concomitant chemoradiation in locally advanced head and neck cancers.
Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
Eswaran P; Azmi KS
J Cancer Res Ther; 2013; 9(3):392-6. PubMed ID: 24125972
[TBL] [Abstract][Full Text] [Related]
10. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
12. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer.
Suzuki M; Nishimura Y; Nakamatsu K; Kanamori S; Koike R; Kawamoto M; Mori K
Jpn J Clin Oncol; 2003 Jun; 33(6):297-301. PubMed ID: 12913084
[TBL] [Abstract][Full Text] [Related]
14. Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck.
MacKenzie R; Balogh J; Choo R; Franssen E
Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):589-95. PubMed ID: 10524410
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Arias de la Vega F; Contreras J; de Las Heras M; de la Torre A; Arrazubi V; Herruzo I; Prieto I; García-Saenz JA; Romero J; Calvo FA;
Ann Oncol; 2012 Apr; 23(4):1005-9. PubMed ID: 21778302
[TBL] [Abstract][Full Text] [Related]
18. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
Guo Y; Ahn MJ; Chan A; Wang CH; Kang JH; Kim SB; Bello M; Arora RS; Zhang Q; He X; Li P; Dechaphunkul A; Kumar V; Kamble K; Li W; Kandil A; Cohen EEW; Geng Y; Zografos E; Tang PZ
Ann Oncol; 2019 Nov; 30(11):1831-1839. PubMed ID: 31501887
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group.
Yoo GH; Moon J; Leblanc M; Lonardo F; Urba S; Kim H; Hanna E; Tsue T; Valentino J; Ensley J; Wolf G
Arch Otolaryngol Head Neck Surg; 2009 Sep; 135(9):869-74. PubMed ID: 19770418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]